Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 20,000 shares at $38.20 ($786K) on 2025-05-15, disclosed to the SEC on 2025-05-19.
Scheduled sale ($786k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.20 | 2,837 | $108K | 13.8% |
| 2 | $38.20 | 2,837 | $108K | 13.8% |
| 3 | $39.46 | 2,779 | $110K | 14.0% |
| 4 | $39.46 | 2,779 | $110K | 14.0% |
| 5 | $39.91 | 4,384 | $175K | 22.3% |
| 6 | $39.91 | 4,384 |
| $175K |
| 22.3% |
| Total | $39.30 avg | 20,000 | $786K | 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |